drugset / Trial / NCT05066672
Phase 2 Study of NV-5138 in Adults With Treatment Resistant Depression
Phase 2
Completed
250 enrolled
Navitor Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
This study will evaluate the efficacy and safety of NV-5138 in adults with TRD
Timeline
- Start
- 2022-01-18
- Primary completion
- 2025-01-21
- Completion
- 2025-01-21
Outcome
Missed primary endpoint
registry analysis (other test); NV-5138 (800 or 1600 mg) vs Placebo; p = 0.7941; Mean Difference (Net) -0.4 (95% CI -3.01 to 2.30); Mixed Models Analysis NCT05066672 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NV-5138 | Small molecule | 800 mg | Oral |
| Subject | NV-5138 | Small molecule | 1600 mg | Oral |
Indications
No indication recorded.